Biomea Fusion IncNASDAQ:BMEA
- LAST PRICE5.7800
- TODAY'S CHANGE (%)-0.0400 (-0.6873%)
- Bid / Lots5.7600/ ---
- Ask / Lots5.7800/ ---
- Open / Previous Close5.8500 / 5.8200
- Day Range
- 52 Week Range
- Volume266,428
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BMEA |
|---|---|---|
| 09:32 ET | 1187 | 5.85 |
| 09:34 ET | 424 | 5.86 |
| 09:36 ET | 300 | 5.8 |
| 09:39 ET | 3150 | 5.83 |
| 09:41 ET | 1462 | 5.84 |
| 09:43 ET | 100 | 5.83 |
| 09:45 ET | 700 | 5.8 |
| 09:52 ET | 200 | 5.82 |
| 09:54 ET | 282 | 5.8 |
| 09:56 ET | 100 | 5.8 |
| 10:01 ET | 700 | 5.76 |
| 10:03 ET | 200 | 5.735 |
| 10:08 ET | 1065 | 5.78 |
| 10:10 ET | 18330 | 5.775 |
| 10:12 ET | 577 | 5.73 |
| 10:15 ET | 100 | 5.75 |
| 10:17 ET | 100 | 5.75 |
| 10:19 ET | 3192 | 5.735 |
| 10:21 ET | 100 | 5.73 |
| 10:24 ET | 500 | 5.75 |
| 10:26 ET | 829 | 5.75 |
| 10:28 ET | 791 | 5.73 |
| 10:30 ET | 200 | 5.74 |
| 10:32 ET | 300 | 5.75 |
| 10:33 ET | 200 | 5.74 |
| 10:35 ET | 300 | 5.735 |
| 10:37 ET | 1498 | 5.76 |
| 10:39 ET | 200 | 5.75 |
| 10:42 ET | 600 | 5.76 |
| 10:44 ET | 332 | 5.78 |
| 10:46 ET | 395 | 5.77 |
| 10:48 ET | 222 | 5.76 |
| 10:50 ET | 100 | 5.76 |
| 10:51 ET | 1904 | 5.75 |
| 10:53 ET | 250 | 5.76 |
| 10:57 ET | 1778 | 5.7899 |
| 11:00 ET | 4750 | 5.8 |
| 11:02 ET | 850 | 5.85 |
| 11:04 ET | 1673 | 5.8499 |
| 11:06 ET | 1400 | 5.8 |
| 11:08 ET | 924 | 5.79 |
| 11:09 ET | 928 | 5.82 |
| 11:18 ET | 1400 | 5.83 |
| 11:20 ET | 1100 | 5.79 |
| 11:22 ET | 100 | 5.795 |
| 11:24 ET | 500 | 5.805 |
| 11:27 ET | 700 | 5.82 |
| 11:29 ET | 1400 | 5.83 |
| 11:31 ET | 970 | 5.87 |
| 11:33 ET | 300 | 5.85 |
| 11:36 ET | 200 | 5.8476 |
| 11:38 ET | 621 | 5.85 |
| 11:40 ET | 200 | 5.86 |
| 11:42 ET | 1900 | 5.88 |
| 11:44 ET | 400 | 5.8812 |
| 11:45 ET | 100 | 5.8601 |
| 11:47 ET | 1041 | 5.89 |
| 11:54 ET | 400 | 5.89 |
| 11:58 ET | 200 | 5.895 |
| 12:00 ET | 300 | 5.88 |
| 12:02 ET | 100 | 5.88 |
| 12:05 ET | 200 | 5.88 |
| 12:07 ET | 1096 | 5.86 |
| 12:09 ET | 100 | 5.85 |
| 12:12 ET | 753 | 5.87 |
| 12:16 ET | 100 | 5.87 |
| 12:20 ET | 206 | 5.86 |
| 12:23 ET | 371 | 5.87 |
| 12:25 ET | 800 | 5.85 |
| 12:27 ET | 700 | 5.85 |
| 12:32 ET | 200 | 5.845 |
| 12:34 ET | 1528 | 5.8599 |
| 12:38 ET | 400 | 5.86 |
| 12:39 ET | 600 | 5.86 |
| 12:41 ET | 100 | 5.86 |
| 12:43 ET | 346 | 5.85 |
| 12:54 ET | 227 | 5.86 |
| 12:56 ET | 300 | 5.865 |
| 12:59 ET | 168 | 5.85 |
| 01:03 ET | 11895 | 5.86 |
| 01:06 ET | 4667 | 5.86 |
| 01:08 ET | 11249 | 5.9 |
| 01:10 ET | 213 | 5.8901 |
| 01:12 ET | 2167 | 5.86 |
| 01:14 ET | 700 | 5.85 |
| 01:15 ET | 100 | 5.845 |
| 01:19 ET | 300 | 5.845 |
| 01:21 ET | 1124 | 5.84 |
| 01:24 ET | 2100 | 5.815 |
| 01:26 ET | 2880 | 5.79 |
| 01:28 ET | 300 | 5.795 |
| 01:30 ET | 6261 | 5.79 |
| 01:32 ET | 621 | 5.76 |
| 01:35 ET | 1995 | 5.79 |
| 01:37 ET | 1020 | 5.79 |
| 01:39 ET | 1328 | 5.8 |
| 01:44 ET | 100 | 5.78 |
| 01:50 ET | 1958 | 5.79 |
| 01:51 ET | 2305 | 5.78 |
| 02:00 ET | 700 | 5.77 |
| 02:02 ET | 200 | 5.76 |
| 02:04 ET | 912 | 5.78 |
| 02:08 ET | 600 | 5.77 |
| 02:11 ET | 400 | 5.78 |
| 02:13 ET | 100 | 5.785 |
| 02:15 ET | 600 | 5.79 |
| 02:18 ET | 100 | 5.79 |
| 02:20 ET | 400 | 5.78 |
| 02:22 ET | 300 | 5.79 |
| 02:24 ET | 831 | 5.79 |
| 02:26 ET | 960 | 5.7978 |
| 02:27 ET | 100 | 5.79 |
| 02:29 ET | 209 | 5.7801 |
| 02:31 ET | 2466 | 5.805 |
| 02:33 ET | 1170 | 5.84 |
| 02:36 ET | 100 | 5.86 |
| 02:40 ET | 870 | 5.87 |
| 02:42 ET | 1400 | 5.8642 |
| 02:44 ET | 1500 | 5.86 |
| 02:47 ET | 100 | 5.86 |
| 02:49 ET | 100 | 5.86 |
| 02:51 ET | 709 | 5.875 |
| 02:54 ET | 468 | 5.86 |
| 02:56 ET | 512 | 5.85 |
| 03:02 ET | 190 | 5.84 |
| 03:07 ET | 1707 | 5.83 |
| 03:12 ET | 500 | 5.82 |
| 03:14 ET | 606 | 5.81 |
| 03:16 ET | 500 | 5.82 |
Today
Yesterday
The Schall Law Firm Is Looking Into Potential Securities Violations By Biomea Fusion Inc And Encourages Investors To Reach Out, from 11:19AM ET on Sunday Aug 18, 2024 by Dow Jones
11:19AM ET on Sunday Aug 18, 2024 by Dow Jones
Aug 16, 2024
The Schall Law Firm Is Investigating Claims Against Biomea Fusion Inc And Asks Shareholders With Losses To Reach Out, from 11:05AM ET on Friday Aug 16, 2024 by Dow Jones
11:05AM ET on Friday Aug 16, 2024 by Dow Jones
Aug 15, 2024
The Schall Law Firm Investigates Claims Against Biomea Fusion Inc And Encourages Investors With Losses To Initiate Contact, from 7:31PM ET on Thursday Aug 15, 2024 by Dow Jones
7:31PM ET on Thursday Aug 15, 2024 by Dow Jones
Aug 14, 2024
The Schall Law Firm Initiates An Investigation Into Claims Against Biomea Fusion Inc And Urges Shareholders With Losses To Get In Touch, from 8:37PM ET on Wednesday Aug 14, 2024 by Dow Jones
8:37PM ET on Wednesday Aug 14, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biomea Fusion Inc | 209.3M | --- | --- |
ATAI Life Sciences NV | 204.2M | -3.4x | --- |
Trevi Therapeutics Inc | 201.1M | -7.6x | --- |
Rezolute Inc | 217.9M | -3.8x | --- |
Zura Bio Ltd | 220.4M | --- | --- |
Pyxis Oncology Inc | 198.0M | -2.9x | --- |
Company Information
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Contact Information
- Headquarters
- 900 Middlefield Road, 4Th FloorREDWOOD CITY, CA, United States 94063
- Phone
- 650-980-9099
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Thomas Butler
- President, Co-Founder, Chief Operating Officer, Director
- Rainer Erdtmann
- Chief Financial Officer
- Franco Valle
- Chief Medical Officer
- Juan Fras
- Independent Director
- Eric Aguiar
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $209.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.2M |
Biomea Fusion Inc does not pay a dividend. | |
Beta | -0.54 |
EPS | $-3.90 |
Book Value | $4.72 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
